Tsumura & Co
TSE:4540
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (9.8), the stock would be worth ¥4 012.24 (9% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.1 | ¥3 688 |
0%
|
| 3-Year Average | 9.8 | ¥4 012.24 |
+9%
|
| 5-Year Average | 10 | ¥4 084.51 |
+11%
|
| Industry Average | 17.5 | ¥7 116.09 |
+93%
|
| Country Average | 13.6 | ¥5 554.81 |
+51%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Tsumura & Co
TSE:4540
|
274.9B JPY | 9.1 | 9.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
870.6B USD | 30.2 | 41.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.4B USD | 21.6 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 12.9 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 22.7 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 15.9 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
279.4B USD | 11.8 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.3 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 10 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 8.8 | 16.9 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 9.8 |
| Median | 13.6 |
| 70th Percentile | 18.1 |
| Max | 414 821 439 |
Other Multiples
Tsumura & Co
Glance View
Tsumura & Co., a venerable name in the herbal medicine industry, traces its roots back to 1893. Emerging from Japan's rich pharmacopeia tradition, the company has carved a niche by blending age-old herbal knowledge with contemporary research and quality control. This synergy allows Tsumura to thrive in the modern marketplace, offering Kampo—a traditional Japanese herbal medicine—as their primary product line. Tsumura stands out in its meticulous approach to sourcing high-quality raw materials, employing state-of-the-art technology to ensure efficacy and safety. This rigorous quality assurance not only honors the integrity of traditional formulas but also aligns with the stringent standards of modern healthcare. In its pursuit of growth, Tsumura expertly navigates the delicate balance between tradition and innovation. The company generates revenue through the sale of its Kampo products, which are widely used in clinics and hospitals across Japan, reflecting a significant integration into the mainstream healthcare system. Additionally, Tsumura's strategic collaborations with pharmaceutical companies expand its reach into international markets. Through educational initiatives, they further advocate for the understanding and acceptance of herbal medicine globally. By continually investing in research and development, Tsumura aims to bolster their product offerings, ensuring that the ancient wisdom of Kampo remains relevant in today's fast-paced, health-conscious world.